Auryxia (ferric citrate)
Hyperphosphatemia in CKD patients on dialysis; Iron deficiency anemia in CKD patients not on dialysis
ApprovedCommercial
Key Facts
Indication
Hyperphosphatemia in CKD patients on dialysis; Iron deficiency anemia in CKD patients not on dialysis
Phase
Approved
Status
Commercial
Company
About Akebia Therapeutics
Akebia Therapeutics is a commercial-stage biopharma with a mission to better the lives of those impacted by kidney disease through innovative therapeutics. The company has achieved significant milestones, including the FDA approval and commercialization of two oral HIF-PHI products, vadadustat and Auryxia, establishing it as a trusted leader in nephrology. Its strategy centers on maximizing the value of its commercial portfolio, advancing its late-stage pipeline in kidney disease complications, and leveraging its fully integrated operational model and deep renal community expertise for sustainable growth.
View full company profile